February 21, 2024
Cancer Cell Market

The Global Cancer Cell Detection Market Driven By Growing Cases Of Cancer

The global cancer cell detection market is majorly driven by the growing prevalence of cancer across the globe. Cancer cell detection devices help identify cancer cells during diagnosis and also helps monitor the effectiveness of cancer treatment during and after therapy. These devices are used to detect cancer at an early stage by analyzing various biomarkers, DNA, and RNA content present in tissues and fluid samples. Cancer cell detection technologies like microscopy, PCR, immunoassays etc can identify abnormal cells and cancer-related mutations to help physicians determine appropriate treatment options.

The global Cancer Cell Detection Market is estimated to be valued at US$ 10799.45 million in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Cancer detection devices help physicians analyze tissue and fluid samples for presence of cancer cells through different methodologies. Cancer involving solid tumors is detected by analyzing biopsied tissue samples under microscopes to identify abnormal cancerous cells. Liquid biopsy techniques detect traces of cancer DNA or RNA circulating in blood which can indicate presence of cancer in early stages. Cancer cell detection also monitors treatment response and detects relapse or recurrence by measuring molecular markers in blood. The growing demand for non-invasive and accurate cancer screening and diagnosis techniques is fueling adoption of advanced cancer cell detection devices globally.

Market key trends:

Development of novel liquid biopsy technologies is a key trend in the cancer cell detection market. Liquid biopsies analyze blood samples non-invasively to detect cancer DNA shed by tumor cells into circulation. Companies are focused on development of highly sensitive liquid biopsy tests that can detect even single mutated DNA molecules in blood to enable early cancer detection. Integration of artificial intelligence and machine learning capabilities is also being explored to improve liquid biopsy analysis accuracy. This would help physicians to detect cancer with minimal invasiveness and enhance screening and diagnosis capabilities significantly over the forecast period.

Porter’s Analysis

Threat of new entrants: The cancer cell market has high set up and operation costs due to strict regulations which acts as a barrier for new companies. Also the established companies have strong brand loyal customers which make it difficult for new entrants.

Bargaining power of buyers: The bargaining power of buyers is moderate since there are several established players in the market providing a wide range of products for buyers to choose from.

Bargaining power of suppliers: The bargaining power of suppliers is low due to presence of many suppliers and buyers importing from different regions of the world.

Threat of new substitutes: There is no direct substitute available for cancer cells currently and development of substitutes require huge investment and time, hence threat is low.

Competitive rivalry: The competitive rivalry in the cancer cell market is high due to presence of established global players providing innovative products and services.

Key Takeaways

The Global Cancer Cell Market Size is expected to witness high growth over the forecast period supported by increasing cancer prevalence, research funding and advancements in therapeutics. The global Cancer Cell Detection Market is estimated to be valued at US$ 10799.45 million in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030.

North America is projected to dominate the cancer cell market during the forecast period owing to presence of key players, increasing awareness about cancer treatment and strong R&D investments and infrastructure in the region.

Key players operating in the cancer cell market are Honeywell International Inc., Siemens AG, General Electric Company, and Schneider Electric SE. The companies are focusing on new product development and enhancing their existing cancer cell technologies through strategic collaborations to gain a competitive edge in the market.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it